Yeliva: Phase I final data

Final data from 16 evaluable patients with advanced solid tumors in an open-label, U.S. Phase I trial

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE